XML 30 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 04, 2022
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 1 on Form 8-K/A (“Form 8-K/A”) amends the Current Report on Form 8-K of Immunic, Inc., a Delaware corporation (the “Company”), filed on August 4, 2022 (the “Original 8-K”). This Form 8-K/A is being filed solely to amend Exhibit 99.2 to the Original 8-K to update information depicted on slide 17 titled “Key Publications in 2022 Provide Clear Evidence of a Direct Link Between Epstein-Barr Virus and MS” and slide 18 titled “Vidofludimus Calcium in Multiple Sclerosis Straightforward Approval Strategy.” No other changes have been made to the Original 8-K or the exhibits thereto.
Document Period End Date Aug. 04, 2022
Entity File Number 001-36201
Entity Registrant Name IMMUNIC, INC.
Entity Central Index Key 0001280776
Entity Tax Identification Number 56-2358443
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1200 Avenue of the Americas
Entity Address, Address Line Two Suite 200
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Country US
Entity Address, Postal Zip Code 10036
City Area Code (332)
Local Phone Number 255-9818
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol IMUX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false